Expert recommendations on venetoclax-based regimens for treatment of newly diagnosed unfit acute myeloid leukemia (2024 version)

VernacularTitle:含维奈克拉方案治疗新诊断不适合强烈化疗急性髓系白血病的专家建议（2024年版）
Keywords: Leukemia, myeloid, acute; Venetoclax; Drug therapy, combination
From: Journal of Leukemia & Lymphoma 2024;33(11):641-648
CountryChina
Language:Chinese
Abstract: Venetoclax is a novel bcl-2 targeted drug for the treatment of acute myeloid leukemia (AML). Clinical guidelines at home and abroad recommend the regimen of venetoclax combined with azacitidine as the standard of care for the newly diagnosed AML patients which are unfit for intensive chemotherapy. The drugs in this regimen are currently included in the China's national reimbursement drug list. A working group consisting of 25 Chinese leukemia experts reached a consensus using the Delphi method and developed guidance covering 9 clinical issues and 25 expert recommendations. These recommendations included the key clinical issues and provided practical guidance for Chinese doctors to standardize the usage of venetoclax-based regimens for treatment of newly diagnosed unfit AML.